Last edition
News about "Gland Pharma"
Gland Pharma Announces Strategic CDMO Partnership with Global Pharmaceutical Company
Gland Pharma has partnered with a global pharmaceutical company to provide end-to-end Contract Development and Manufacturing Organisation (CDMO) services across commercial and pipeline products throughout their lifecycle.
Gland Pharma | 11/08/2026 | By News Bureau
Gland Pharma and Neuland Partner for Sterile API Manufacturing
Gland Pharma and Neuland Laboratories have partnered to expand sterile Active Pharmaceutical Ingredient (API) manufacturing through a new state-of-the-art current Good Manufacturing Practice (GMP) sterile manufacturing suite.
Gland Pharma | 06/08/2026 | By News Bureau
Gland Pharma Receives US FDA Approval for Generic Sugammadex Injection
Gland Pharma has secured US FDA approval for its generic Sugammadex Injection and launched the product in the US, strengthening its injectable portfolio in a market valued at approximately USD 1.6 billion annually.
Gland Pharma | 29/07/2026 | By News Bureau
The partnership among Orbicular Pharmaceutical Technologies, Gland Pharma and Apotex, achieves first ANDA approval with Competitive Generic Therapy designation, gaining six-month exclusivity for complex multivitamin injectable in the United States.
Gland Pharma | 16/04/2026 | By News Bureau | 275
Gland Pharma Secures USFDA Approval for Ready-to-Use Vasopressin Injection
The product is bioequivalent and therapeutically equivalent to the reference drug Vasostrict. Vasopressin is indicated for adults with vasodilatory shock who remain hypotensive despite adequate fluid resuscitation and catecholamine support.
Gland Pharma | 27/08/2025 | By Darshana | 267
Gland Pharma Ltd. has received USFDA approval for its generic Norepinephrine Bitartrate in 5 percent Dextrose Injection, securing First-to-File status with 180 days of exclusivity in the US market.
Gland Pharma | 16/08/2025 | By Mrinmoy Dey | 350
Gland Pharma Gets FDA Approval for Phytonadione Injectable Emulsion
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin KI1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.
Gland Pharma | 16/12/2024 | By Aishwarya | 939
Six Pharma Firms Plans to Build Green Pharma Units in Telangana
As per the MoUs, the MSN Group will establish a manufacturing unit and an R&D centre and Aurobindo Pharma and Laurus Labs will set up formulation units.
Gland Pharma | 25/11/2024 | By Aishwarya | 530
Gland Pharma Reports Revenue of INR 14,058 Million in Q2FY25
Gland Pharma has reported a consolidated revenue of INR 14,058 million for Q2 FY25, marking a 2 percent increase compared to INR 13,734 million in Q2 FY24.
Gland Pharma | 05/11/2024 | By Aishwarya | 1232
Gland Pharma Welcomes Shyamakant Giri as New CEO
Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in Indian and multinational organizations across Asia, Africa, MENA & LATAM markets.
Gland Pharma | 21/10/2024 | By Aishwarya | 1188
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy